NASDAQ:KMPH Zevra Therapeutics (KMPH) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$4.48▼$6.2752-Week Range N/AVolume64,100 shsAverage Volume189,500 shsMarket Capitalization$200.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zevra Therapeutics alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Zevra Therapeutics Stock (NASDAQ:KMPH)KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here KMPH Stock News HeadlinesJuly 19, 2024 | msn.comInsiders Buying Zevra Therapeutics And 1 Other StockMay 9, 2024 | markets.businessinsider.comStrong Buy Rating for Zevra Therapeutics Based on Solid Financials and Promising Drug PipelineJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 9, 2024 | msn.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comZevra Therapeutics GAAP EPS of -$0.40 beats by $0.08, revenue of $3.42M misses by $0.34MMarch 4, 2024 | marketwatch.comZevra Therapeutics Shares Fall After FDA Extends Arimoclomol ReviewFebruary 20, 2024 | yahoo.comBrisbane, Australia - Weather Forecasts | Maps | News - Yahoo WeatherFebruary 17, 2024 | yahoo.comChristchurch, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.January 11, 2024 | yahoo.comGreater Bendigo, Australia - Weather Forecasts | Maps | News - Yahoo WeatherJanuary 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zevra Therapeutics Amid Positive Regulatory Developments and Strong Market PositioningJanuary 8, 2024 | markets.businessinsider.comZevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type CJanuary 6, 2024 | yahoo.comWellington, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherDecember 27, 2023 | msn.comZevra seeks FDA nod for rare disease therapy arimoclomolDecember 27, 2023 | marketwatch.comZevra Therapeutics Refiles Arimoclomol Application With FDADecember 23, 2023 | yahoo.comQueenstown, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherDecember 11, 2023 | yahoo.comMelbourne, Australia - Weather Forecasts | Maps | News - Yahoo WeatherDecember 11, 2023 | yahoo.comOroquieta City, Philippines - Weather Forecasts | Maps | News - Yahoo WeatherSee More Headlines Receive KMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/30/2022Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KMPH CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net Margins-328.56% Pretax Margin-335.26% Return on Equity-16.12% Return on Assets-14.17% Debt Debt-to-Equity Ratio0.14 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$10.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow23.28 Book Value$3.63 per share Price / BookN/AMiscellaneous Outstanding Shares34,505,000Free Float34,125,000Market Cap$200.47 million OptionableOptionable Beta2.16 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesRichard W. PascoeChief Executive Officer & DirectorTravis C. MicklePresident & DirectorR. LaDuane CliftonChief Financial Officer, Secretary & TreasurerSven GuentherChief Scientific OfficerDaniel GalloSenior Vice President-Medical AffairsKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHPliant TherapeuticsNASDAQ:PLRXEvolusNASDAQ:EOLSSage TherapeuticsNASDAQ:SAGEWave Life SciencesNASDAQ:WVEView All Competitors KMPH Stock Analysis - Frequently Asked Questions How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:KMPH) released its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative net margin of 328.56% and a negative trailing twelve-month return on equity of 16.12%. When did Zevra Therapeutics IPO? Zevra Therapeutics (KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Exelixis (EXEL) and BioCryst Pharmaceuticals (BCRX). This page (NASDAQ:KMPH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.